Evidence map›Paper›PMID 37573434›Full record

ArticleNPJ vaccines2023

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells.

Robert G E Krause, Thandeka Moyo-Gwete, Simone I Richardson, Zanele Makhado, Nelia P Manamela, Tandile Hermanus, Nonhlanhla N Mkhize, Roanne Keeton, Ntombi Benede, Mathilda Mennen and 15 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 3 countries.

Robert G E KrauseAfrica Health Research Institute, Durban, 4001, South Africa.
Thandeka Moyo-GweteNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-4269-9281
Simone I RichardsonNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-7678-2609
Zanele MakhadoNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.ORCID http://orcid.org/0000-0002-8371-6180
Nelia P ManamelaNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Tandile HermanusNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Nonhlanhla N MkhizeNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Roanne KeetonInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Ntombi BenedeInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
Mathilda MennenDepartment of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa.
Sango SkelemDepartment of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa.
Farina KarimAfrica Health Research Institute, Durban, 4001, South Africa.
Khadija KhanAfrica Health Research Institute, Durban, 4001, South Africa.ORCID http://orcid.org/0000-0001-7565-7400
Catherine RiouInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.ORCID http://orcid.org/0000-0001-9679-0745
Ntobeko A B NtusiInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.ORCID http://orcid.org/0000-0003-2347-7883
Ameena GogaSouth African Medical Research Council, Cape Town, South Africa.
Glenda GraySouth African Medical Research Council, Cape Town, South Africa.
Willem HanekomAfrica Health Research Institute, Durban, 4001, South Africa.ORCID http://orcid.org/0000-0003-3070-6154
Nigel GarrettCentre for the AIDS Program of Research in South Africa, Durban, South Africa.ORCID http://orcid.org/0000-0002-4530-234X
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.ORCID http://orcid.org/0000-0002-0755-4386
Andreas GrollDepartment of Statistics, TU Dortmund University, Dortmund, Germany.ORCID http://orcid.org/0000-0001-6787-9118
Alex SigalAfrica Health Research Institute, Durban, 4001, South Africa.ORCID http://orcid.org/0000-0001-8571-2004
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-8719-4028
Wendy A BurgersInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.ORCID http://orcid.org/0000-0003-3396-9398
Alasdair LeslieAfrica Health Research Institute, Durban, 4001, South Africa. al.leslie@ahri.org.ORCID http://orcid.org/0000-0003-2538-6467
National Health Laboratory Service · ZAUniversity of Cape Town · ZAAfrica Health Research Institute · ZACentre for the AIDS Programme of Research in South Africa · ZASouth African Medical Research Council · ZADesmond Tutu HIV Foundation · ZATU Dortmund University · DE

Funding

Wellcome Trust
6 · The paper itself

Abstract

Neutralizing antibodies strongly correlate with protection for COVID-19 vaccines, but the corresponding memory B cells that form to protect against future infection are relatively understudied. Here we examine the effect of prior SARS-CoV-2 infection on the magnitude and phenotype of the memory B cell response to single dose Johnson and Johnson (Ad26.COV2.S) vaccination in South African health care workers. Participants were either naïve to SARS-CoV-2 or had been infected before vaccination. SARS-CoV-2-specific memory B-cells expand in response to Ad26.COV2.S and are maintained for the study duration (84 days) in all individuals. However, prior infection is associated with a greater frequency of these cells, a significant reduction in expression of the germinal center chemokine receptor CXCR5, and increased class switching. These B cell features correlated with neutralization and antibody-dependent cytotoxicity (ADCC) activity, and with the frequency of SARS-CoV-2 specific circulating T follicular helper cells (cTfh). Vaccination-induced effective neutralization of the D614G variant in both infected and naïve participants but boosted neutralizing antibodies against the Beta and Omicron variants only in participants with prior infection. In addition, the SARS-CoV-2 specific CD8+ T cell response correlated with increased memory B cell expression of the lung-homing receptor CXCR3, which was sustained in the previously infected group. Finally, although vaccination achieved equivalent B cell activation regardless of infection history, it was negatively impacted by age. These data show that phenotyping the response to vaccination can provide insight into the impact of prior infection on memory B cell homing, CSM, cTfh, and neutralization activity. These data can provide early signals to inform studies of vaccine boosting, durability, and co-morbidities.

Identifiers

PMID37573434
PMCPMC10423246
OpenAlexW4385780284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.